Shots:

• The P-III STORM CHASER study involves assessing AZD7442 (300mg) vs PBO for the post-exposure prevention of COVID-19 in 1-121 participants in 59 sites across the UK and US
• The study did not meet its 1EPs and showed 33% reduction in risk of developing symptomatic COVID-19
• In a pre-planned analysis of PCR positive & negative participants- AZD7442 showed 73% reduction in the risk of developing symptomatic COVID-19 in participants who were PCR negative at time of dosing. In a post-hoc analysis- in participants who were PCR negative at baseline- AZD7442 reduced the risk of developing symptomatic COVID-19 by 92% more than 7days following dosing- and by 51% up to 7 days following dosing

Ref: AstraZeneca | Image: New Europe